Who We Are
Invivocue is a bioscience company that aims to support medical and pharmaceutical research through its humanized rodent models.
Invivocue was formed as a joint venture between Invitrocue, an innovative life sciences company providing in vitro liver models for drug toxicology testing, as well as 3D patient-derived organoid technology for personalised oncology, and Dr Chen Qing Feng, a Senior Principal Investigator at A*STAR Singapore, Institute of Molecular and Cell Biology, whose research expertise focused on humanized mouse models for various disease applications.
Tapping into our expertise in in vitro and animal disease models in wild-type and humanized mice, we want to be your preferred drug discovery and development partner, by providing a quality one-stop solution to address your needs from target discovery, validation to pre-clinical development, and eventually advancing to clinical trials.
Our animal models have enabled research in areas such as oncology, toxicity, liver disease, auto-immune and infectious diseases. These research have been published in numerous well-regarded journals, including Cancers, Science Advances, Hepatology, PNAS, Gut, Blood and Nature Communications.
What We Do
Bridging the Gap: Revolutionizing Drug Development
We understand the challenges faced by researchers when translating preclinical findings into meaningful clinical outcomes. At Invivocue, we bridge the critical gap between preclinical and clinical research by offering contract research and development services to academic institutions and biopharmaceutical companies in preclinical testing using humanised mice models. Leveraging on our proprietary technology in the production of humanised mice, we offer to our Clients humanised mice which can be shipped to their facilities (as Products) or conduct the experiments in our laboratory in accordance to Clients’ study design (as Services). Our humanized mice model plays a crucial role in expediting the development of groundbreaking treatments that hold the potential to transform the future of medicine.
OUR VISION
To develop and provide a simpler, better and more affordable humanized mice model for drug efficacy and safety assessment.
People/Leadership
-
Dr Steven Fang is Founder and Executive Director of Invitrocue Limited, partner at Clearbridge Accelerator and was the Group CEO of CordLife Ltd. He has been awarded with the World Economic Forum Technology Pioneer Award, Ernst & Young Entrepreneur of the Year for New Enterprise, Spirit of Enterprise and the Asia Pacific Entrepreneurship Award’s Outstanding Entrepreneur Award.
Dr Fang has over two decades of experience in building biotechnology and life sciences companies. Dr Fang was the Group CEO of CordLife Ltd, which he founded in May 2001; the company has since grown with operations in Singapore, Hong Kong, Jakarta, Indonesia, Kolkata, India, and Australia. CordLife was listed on the Australian Stock Exchange in 2004 and spun off a separate entity in 2012, which subsequently was listed on the Singapore Stock Exchange. Prior to CordLife, Dr Fang held various management positions in Becton Dickinson, Baxter Healthcare and Sterling Pharmaceuticals (now part of GSK).
-
Dr. Chen Qingfeng is currently a Senior Principal Investigator at the Institute of Molecular and Cell Biology (IMCB) at Singapore’s Agency for Science, Technology & Research (A*STAR). Alongside his role at IMCB, he is also holding Joint positions with local research institutes and hospitals and adjunct Associate Professor in National University of Singapore. Dr. Chen’s research expertise lies in developing humanized mouse models with various human biological systems and the applications of these models in human diseases.
-
Ms. Susan Chia brings close to 20 years of experience in pharmaceutical and healthcare industry, having held positions in sales and clinical research with Glaxo Wellcome (now GSK), Johnson and Johnson and Covance. Ms. Chia was one of the pioneers in the set up of Contract Research Organisation (CRO) in Singapore and Asia, before the company became a public listed company in NYSE as Covance. Over her 13 years with Covance, she served in various leadership positions, including Client Relationship Director, Administrative Head Singapore, and Director of Clinical Operations, Asia Pacific. In her last position as Director of Clinical Operations, she had responsibilities for Phase II to IV clinical trial management in 12 countries, including Australia, China, Korea and Southeast Asia. Ms. Chia holds a Bachelor of Science degree from the National University of Singapore, with major in Chemistry and Microbiology. She has also received a Gold Award for Graduate Diploma in Marketing from the Marketing Institute of Singapore.
-
Zhisheng HER is currently Associate Director, Technology at Invivocue, overseeing the development of in-house in vivo services in wild-type and humanized mice disease models. He provides leadership to laboratory operations teams for in-vivo products and services, and manages the operations team’s progress from project initiation to project completion. Zhisheng brings extensive experience in the areas of animal disease modelling, with significant success in translating scientific research into industrial commercialisation. In addition to his primary job functions in Invivocue, Zhisheng is also a Research Fellow in the Humanized Mice Unit in Institute of Molecular & Cell Biology at A*STAR. Driven by his passion in immunology and cancer biology, Zhisheng has contributed to the establishment of humanized mice disease models in cancers, toxicity, metabolic, and autoimmune diseases. These research efforts are aimed at utilising humanized mice to evaluate the safety and efficacy of treatment strategies for human diseases. The knowledge and experience gained laid the foundation for Zhisheng to enable translatability of scientific discoveries to commercial applications in Invivocue. As the Team Lead at Invivocue, Zhisheng engages with all potential Clients at the early stage of project planning and provides valuable insights and technical expertise to help guide experiment design and execution plan. Zhisheng received his Bachelor’s degree (BSc) in Biological Sciences from Nanyang Technological University (NTU), Singapore in 2008, and his Doctor of Philosophy (PhD) in Medicine from National University of Singapore (NUS), Singapore in 2013. He was awarded the Nanyang Scholarship from NTU for the 2005-2008 academic years, and the President’s Graduate Fellowship from NUS for the 2009-2013 academic years.